10 news items
HC Wainwright & Co. Maintains Buy on Black Diamond Therapeutic, Lowers Price Target to $11
BDTX
16 May 24
HC Wainwright & Co. analyst Robert Burns maintains Black Diamond Therapeutic (NASDAQ:BDTX) with a Buy and lowers the price target from $12 to $11.
Black Diamond Therapeutic Q1 2024 GAAP EPS $(0.35) Beats $(0.44) Estimate
BDTX
9 May 24
Black Diamond Therapeutic (NASDAQ:BDTX) reported quarterly losses of $(0.35
Black Diamond Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update
BDTX
9 May 24
NEWSWIRE) -- Black Diamond Therapeutics, Inc. (NASDAQ:BDTX), a clinical-stage
Garry Menzel joins GHO Capital as Operating Partner
ADAP
BDTX
DVA
23 Apr 24
physician services, and later became a founding Board member of Black Diamond Therapeutics
Wedbush Maintains Outperform on Black Diamond Therapeutic, Raises Price Target to $16
BDTX
8 Apr 24
Wedbush analyst Robert Driscoll maintains Black Diamond Therapeutic (NASDAQ:BDTX) with a Outperform and raises the price target from $10 to $16.
7987uet118vy4fnh2c3ni28
BDTX
8 Apr 24
pqipfgp34ze9ofsazrckef82hyur4loowt4fmpuu
BDTX
3 Apr 24
) -- Black Diamond Therapeutics, Inc
9i99znqoo1vt08ihz8t
BDTX
13 Mar 24
Wedbush analyst Robert Driscoll reiterates Black Diamond Therapeutic (NASDAQ:BDTX) with a Outperform and maintains $10 price target.
a89xb4rynazyzcgkph3vyd
BDTX
12 Mar 24
Black Diamond Therapeutic (NASDAQ:BDTX) reported its Q4
z6ertp1lewxjlde4rjhhg5o9cwgpcdtpy3481b34cuoi04ar1ufo6
BDTX
12 Mar 24
Black Diamond Therapeutic (NASDAQ:BDTX) reported quarterly losses of $(0.34
- Prev
- 1
- Next